The company offers Viacord service for pediatric bone marrow transplantations, which involves the collection, testing, processing, and preserving of umbilical cord blood.
Its proprietary technology, Selective Amplification technology, enables isolation, purification, and expansion of stem cell population.
The company develops a cord blood-derived stem cell therapeutic, CB001, stem cell therapy product candidate, which is in phase I clinical development.
CB001 would be used in for bone marrow and other crude cell mixtures used in stem cell transplants.
It also develops Viacyte, a product candidate for cryopreserving and storing human oocytes.
The company has collaboration, licensing, and strategic relationships with Amgen technology, GlaxoSmithKline and Glaxo Group, Tyho Galileo Research Laboratory, Genzyme, and Massachusetts General Hospital.
ViaCell was incorporated as t.
Breeders, Inc.
in 1994 and changed its name to ViaCell, Inc.
in 2000.
The company is headquartered in Cambridge, Massachusetts.
